Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

NCT04504331 is registered in ClinicalTrials.gov with Jennifer Lee Caswell-Jin as lead sponsor.

NCT NCT04504331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04504331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Lead sponsor
Jennifer Lee Caswell-Jin
Phase
Phase 1
Overall status
Terminated
Start date
October 13, 2020
Completion date
October 22, 2021
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, er positive breast cancer, her2-negative breast cancer, pr-positive breast cancer